This analysis established plasma NfL as a reasonably likely surrogate endpoint, which, when combined with the totality of evidence, supported the accelerated approval of tofersen for SOD1-ALS, addressing an urgent need for this rare and life-threatening disease [57]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.